组织型纤溶酶原激活剂(t-PA)突变体工程细胞株生物学特性分析

t-PA突变体工程细胞株FSGGI48形态与其亲代细胞CHO-dhfr相似呈多角形,类似上皮细胞。在MTX加压至5×10~(-6)mol/L时,少数细胞形态略变瘦长,但仍呈多角形,因此该工程细胞株形态正常。抗体中和抑制试验及纤维蛋白板80℃加热试验显示,FSGGI48细胞表达产物与st-PA的活性均能被抗t-PA抗体所抑制,而胰酶的活性则不被抑制,且二者在80℃加热的纤维蛋白板上均不产生溶解圈,胰酶则产生溶解圈,由此可知,该细胞株表达产物为特异的rt-PA产品。细胞无血清培养上清经FA-PA检测,亚克隆株表达水平为4000IU/10~6细胞/24h。分别测定冻存3个月后复苏和体外传代3个月以上细胞的表达水平,结果显示部分亚克隆细胞株表达水平下降,多数仍为3000-4000IU/10~6细胞/24h,说明细胞株稳定性好。裸鼠试验表明,该工程株活细胞、细胞DNA、纯化的细胞表达产物均无致瘤性。支原体检查结果为阴性。染色体分析显示,FSGGI48细胞与其亲代细胞(CHO-dhfr细胞)染色体数目相同均为20条,但均有不同程度不同类型的畸变。CHO-dhfr细胞畸变率为6%。该工程细胞的畸变率为15%-18%,在允许范围内。结果证明,t-PA突变体细胞株FSGGI48为性能优良的工程细胞株。     

野生型组织型纤溶酶原激活剂(t-PA)工程细胞株生物学特性分析

野生型t-PA工程细胞4B3形态与亲代细胞CHO-dhfr-相似呈多角形,类似上皮细胞。在MTX加压达5×10~(-7)mol/L时,少数细胞略变瘦长,但仍显多角形,形态正常。细胞无血清培养上清经FAPA检测,亚克隆株表达水平为10~6细胞4000～5000IU/24h。细胞经体外传代3个月及冻存3个月后复苏,部分亚克隆株表达水平下降,多数仍为10~6细胞4000IU/24h,表明4B3细胞株稳定性好。裸鼠试验表明,该工程株活细胞、细胞DNA、纯化的4B3rt-PA均无致瘤性病毒,支原体检查为阴性。遗传特性分析表明,该工程细胞与其亲代细胞CHO-dhfr-细胞染色体数均为20条,均有不同程度不同类型的畸变。该工程细胞的畸变率为16％。CHO-dhfr-细胞畸变率为6％。属正常范围。结果表明4B3细胞株为高效表达的性能优良的工程细胞株。     

人组织型纤溶酶原激活剂（t—PA）突变体FrGGI的构建,表达及特性…

为了获得半衰期延长,特异活性提高及具有ＰＡＩ－１抗性的新型ｔ－ＰＡ溶性剂,利用基因重组及定位突变技术构建了ｔ－ＰＡ的Ｋ１、Ｋ２区糖基化位点消除,ＰＡＩ－１结合位点缺失,Ｆ与Ｅ区连接序列Ｈｉｓ４４￣Ｓｅｒ５０置换为纤粘蛋白Ｉ型Ｆ区间连接序列Ｇｌｕ Ｓｅｒ Ｌｙｓ Ｐｒｏ Ｇｌｕ Ａｌａ Ｇｌｕ Ｇｌｕ的ｔ－ＰＡ组合突变体ＦｒＧＧＩ,并在中国仓鼠卵巢细胞中获得了高效表达,对表达产物的生物学特性分析表明     

组织型纤溶酶原激活剂突变体细胞t—PA基因拷贝数测定及分析

组织型纤溶酶原激活剂（t—PA）溶栓特异性高,但半衰期短。本组构建了增强纤维蛋白亲合力和延长半衰期的t—PA突变体表达细胞株。测定工程细胞株基因拷贝数是细胞生物学特性鉴定的一个方面。我们采用狭缝杂交法和SouthernBlot法对该细胞株t—PA基因进行了拷贝数测定,结果为30—60个拷贝。     

人组织型纤溶酶原激活剂（t－PA）突变体FrGGI的构建、表达及特性分析

为了获得半衰期延长,特异活性提高及具有ＰＡＬ－１抗性的新型ｔ－ＰＡ溶栓剂,利用基因重组及定位突变技术构建了ｔ－ＰＡ的Ｋ１、Ｋ２区糖基化位点消除,ＰＡＩ－１结合位点缺失,Ｆ与Ｅ区连接序列Ｈｉｓ４４～Ｓｅｒ５０置换为纤粘蛋白Ⅰ型Ｆ区间连接序列ＧｌｕＳｅｒＬｙｓＰｒｏＧｌｕＡｌａＧｌｕＧｌｕ的ｔ－ＰＡ组合突变体ＦｒＧＧＩ,并在中国仓鼠卵巢细胞中获得了高效表达。对表达产物的生物学特性分析表明,ＦｒＧＧＩ在大鼠血浆中的半衰期延长了１５倍,并获得了ＰＡＩ－１抗性,是一株很有希望的新型溶栓剂候选株。     

纤溶酶原激活剂抑制物2型的结构与功能

纤溶酶原激活剂抑制物２型具纤溶抑制活性,是尿激酶特异的抑缺点蛾。ｕＰＡ在肿瘤浸润过程中起了十分关键的作用,ＰＡＩ－２亦因此成为当今研究的热点。     

人组织型纤溶酶原激活剂（t—PA）组合突变体FrGGl在CHO细胞中的…

为了得到ｔ－ＰＡ组合突体ＦｒＧＧｌ在ＣＨＯ细胞中的高效表达,将表达质粒筛选基因启动子上游的增强子（ｅｎｈａｎｃｅｒ）去除,构建了ＦｒＧＧｌ真核表达质粒ｐＺＬＦｒＧＧＩ。酶切线化后,采用大剂量ＤＮＡ电击介导法,转染ｄｈｆｒ基因缺陷型中仓鼠卵巢细胞系（ＣＨＯ－ｄｈｆｒ）。氨甲喋呤（ＭＴＸ）筛选转染细胞,混合加压,挑选克隆,在１×１０＾－７ｍｏｌ／ＬＭＴＸ压力下,获得表达水平达１５００～２５００ＩＵ／１     

Increased tissue-plasminogen activator (t-PA) levels in patients under oral anticoagulant therapy

The fibrinolytic system was investigated in 30 patients under oral anticoagulant therapy, and in 23 control patients not receiving oral anticoagulants. Patients under oral anticoagulant therapy had significantly higher tissue-plasminogen activator (t-PA) antigen levels than patients in the control group. Mean t-PA levels before venous occlusion were 18.4 ng/ml in the anticoagulated patients vs. 7.9 ng/ml in the control patients (p less than 0.001). After venous occlusion for 10 minutes, t-PA levels were 45.0 ng/ml in the anticoagulated patients and 24.2 ng/ml in the control patients (p less than 0.01). Plasminogen activator inhibitor (PAI) capacity was not significantly different in the two groups before venous occlusion (VO) but differed slightly (p less than 0.05) after VO. The net decrease in euglobulin lysis time (ELT) after venous occlusion (= ELT before VO - ELT after VO), indicating the relative potency of the fibrinolytic activity in blood, was also significantly higher in the anticoagulated patients (median 240 min vs. 125 min, p less than 0.001). These data indicate that oral anticoagulant therapy increases the fibrinolytic activity in blood, and thus may have an additional therapeutic effect in addition to anticoagulation.     

Structure and function of human tissue-type plasminogen activator (t-PA)

Full-length tissue-type plasminogen activator (t-PA) cDNA served to construct deletion mutants within the N-terminal "heavy" (H)-chain of the t-PA molecule. The H-chain cDNA consists of an array of structural domains homologous to domains present on other plasma proteins ("finger," "epidermal growth factor," "kringles"). These structural domains have been located on an exon or a set of exons. The endpoints of the deletions nearly coincide with exon-intron junctions of the chromosomal t-PA gene. Recombinant t-PA deletion mutant proteins were obtained after transient expression in mouse Ltk- cells, transfected with SV40-pBR322-derived t-PA cDNA plasmids. It is demonstrated that the serine protease moiety of t-PA and its substrate specificity for plasminogen is entirely contained within the C-terminal "light" (L)-chain of the protein. The presence of cDNA, encoding the t-PA signal peptide preceding the remaining portion of t-PA, suffices to achieve secretion of (mutant) t-PA into the medium. The stimulatory effect of fibrin on the plasminogen activator activity of t-PA was shown to be mediated by the kringle K2 domain and, to a lesser extent, by the finger domain. The other domains on the H-chain, kringle K1, and the epidermal growth-factor-like domain, do not contribute to this property of t-PA. These findings correlate well with the fibrin-binding properties of the rt-PA deletion-mutant proteins, indicating that stimulation of the activity is based on aligning of the substrate plasminogen and its enzyme t-PA on the fibrin matrix. The primary target for endothelial plasminogen activator inhibitor (PAI) is located within the L-chain of t-PA. Deleting specific segments of t-PA H-chain cDNA and subsequent transient expression in mouse Ltk- cells of t-PA deletion-mutant proteins did not affect the formation of a stable complex between mutant t-PA and PAI.     

Production of tissue plasminogen activator (t-PA) in Aspergillus niger

A protease-deficient strain of Aspergillus niger has been used as a host for the production of human tissue plasminogen activator (t-PA). In defined medium, up to 0.07 mg t-PA (g biomass)(-1) was produced in batch and fed-batch cultures and production was increased two- to threefold in two-phase batch cultures in which additional glucose was provided as a single pulse at the end of the first batch growth phase. Production was increased [up to 1.9 mg t-PA (g biomass)(-1)] by the addition of soy peptone to the defined medium. The rate of t-PA production in batch cultures supplemented with soy peptone (0.2 to 0.6 mg t-PA L(-1) h(-1)) was comparable to rates observed previously in high-producing mammalian or insect cell cultures. In glucose-limited chemostat culture supplemented with soy peptone, t-PA was produced at a rate of 0.7 mg t-PA L(-1) h(-1). Expression of t-PA in A. niger resulted in increased expression of genes (bipA, pdiA, and cypB) involved in the unfolded protein response (UPR). However, when cypB was overexpressed in a t-PA-producing strain, t-PA production was not increased. The t-PA produced in A. niger was cleaved into two chains of similar molecular weight to two-chain human melanoma t-PA. The two chains appeared to be stable for at least 16 h in culture supernatant of the host strain. However, in general, <1% of the t-PA produced in A. niger was active, and active t-PA disappeared from the culture supernatant during the stationary phase of batch cultures, suggesting that the two-chain t-PA may have been incorrectly processed or that initial proteolytic cleavage occurred within the proteolytic domain of the protein. Total t-PA (detected by enzyme-linked immunoassay) also eventually disappeared from culture supernatants, confirming significant extracellular proteolytic activity, even though the host strain was protease-deficient.     

Increased productivity of recombinant tissular plasminogen activator (t-PA) by butyrate and shift of temperature: a cell cycle phases analysis

Directed control of cell metabolism by a modification of the physicochemical conditions (presence of Na-butyrate and modification of the temperature) was used to modulate the productivity of human recombinant tissular plasminogen activator (t-PA) expressed under control of SV40 promoter in Chinese Hamster Ovary (CHO) cell lines. We showed that both by adding Na-butyrate or lowering temperature from 37 °C to 32 °C there is an increase in the amount of t-PA excreted, while cell growth is significantly reduced. The treatments also increased the intracellular amount of t-PA. We measured the distribution of cell cycle phases by cytometry and used a modification of the equations of Kromenaker and Srienc (1991, 1994 a, b) to analyse the intracellular t-PA production rate in the different cell cycle phases. Intracellular t-PA was shown to accumulate in G1 phase in all conditions (at 37 °C, at 32 °C and in presence of butyrate). Moreover, we have shown that the distribution of the time cells treated by butyrate are maintained in the G1cell cycle phase is significantly increased. t-PA produced in the different cell culture conditions tested was analysed by zymogram and western blotting: neither butyrate, neither the shift of temperature changed significantly the overall quality of the protein. The N-glycan patterns of recombinant human t-PA was also analysed with carbohydrate-specific lectins. Butyrate caused a transitory increase in N-linked complex high-mannose oligosaccharides without any effect on the sialic acid content of t-PA. This revised version was published online in July 2006 with corrections to the Cover Date.     

Binding of tissue-type plasminogen activator (t-PA) to Neisseria meningitidis and Haemophilus influenzae

Abstract Forty-nine bacterial strains representing five species known to interact with human plasminogen were tested for the ability to bind the two major human plasminogen activators, t-PA and urokinase. The bacterial species tested included Haemophilus influenzae, Neisseria meningitidis, Streptococcus pyogenes, Streptococcus equisimilis and human group G streptococci. All N. meningitidis and 11 of 14 H. influenzae strains displayed substantial binding of t-PA with values in the range of 20–46%. On the contrary, none of the streptococcal strains bound significant amounts of tPA. With urokinase no binding could be found for any of the bacterial species tested. Scatchard analysis with a selected H. influenzae strain (HI23354) demonstrated 10 000 receptors per bacterium for t-PA with a K _d value of about 20 nmol l⁻¹. The corresponding values with a selected N. meningitidis strain (Mo 52) was 8500 receptors per bacterium and 70 nmol l⁻¹. t-PA binding could be reduced about 40% by the addition of 10 nmol l⁻¹ of the lysine analogue ϵ-aminocaproic acd (EACA) whereas no inhibitory effect could be demonstrated with arginine. Addition of 2 μmol l⁻¹ of plasminogen which is enough to occupy all bacterial sites for plasminogen did not interfere with the t-PA binding, suggesting that the receptors for t-PA and plasminogen are distinct. Using very high plasminogen concentrations however, t-PA binding could be reduced by about 50% possibly due to an interaction between t-PA and plasminogen in the fluid phase. Our results demonstrate the occurrence of a previously unknown type of bacterial receptor that is capable of specifically binding t-PA.     

Conformational similarities between one-chain and two-chain tissue plasminogen activator (t-PA): implications to the activation mechanism on one-chain t-PA.

Tissue plasminogen activator (t-PA) is an exceptional serine protease, because unlike most other serine protease zymogens single-chain tissue plasminogen activator (sct-PA) possesses a substantial amount of proteolytic activity. The unusual reaction of sct-PA afforded the opportunity to directly compare the active site environment of sct-PA and two-chain tissue plasminogen activator (tct-PA) in solution through the application of a series of nitroxide spin labels and fluorophores. These labels, which have been previously shown to covalently label the catalytic serine of other serine proteases, inactivated both sct-PA and tct-PA. The labels can be divided into two classes: those which form tetrahedral complexes (sulfonates) and those which form trigonal complexes (anthranilates). Those which formed tetrahedral complexes were found to be insensitive to structural differences between sct-PA and tct-PA at the active site. In contrast, those which formed trigonal complexes could differentiate and monitor the sct-PA to tct-PA conversion by fluorescence spectroscopy. Models of the structure of sct-PA and tct-PA were constructed on the basis of the known X-ray structures of other serine protease zymogen and active enzyme forms. One of the nitroxide spin labels was modeled into the sct-PA and tct-PA structures in two possible orientations, both of which could be sensitive to structural differences between sct-PA and tct-PA. These models formed the structural rationale used to explain the results obtained with the "tetrahedral" and "trigonal" probes, as well as to offer a possible explanation for the unique reactivity of sct-PA.     

Production and characteristics of a Djzungarian hamster cell line (DX-TK-) resistant to 5-bromodeoxyuridine]

New biochemically marked Djungarian hamster cell line (DX-TK-) was established. These cells are resistant to 5-bromodeoxyuridine (25 mkg/ml) and deficient in thymidine kinase activity (TK-). Due to this biochemical defect they have lost the ability to grow in HAT medium. DX-TK- cells are malignant. They grow as tumours after the inoculation to newborn Djungarian hamsters. Tumorigenecity of DX-TK- cells was decreased as compared with the parent TK+ cell line. DX-TK- cell line is a hypodiploid cell culture (26 chromosomes) with 7 chromosome markers easily identified by means of G-band staining. This line is a new model for somatic cell genetic experiments, particularly for somatic cell hybridization.